Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1150-1159

  Umazume, Kazuhiko ^a   Liu, LanHsin ^a   Scott, Patrick A ^a   Fernandez de Castro, Juan P ^a   McDonald, Kevin ^a   Kaplan, Henry J ^a   Tamiya, Shigeo ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BRUTON TYROSINE KINASE; CALVASCULIN; DASATINIB; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEMALE; HISTOLOGY; IMMUNOCYTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; SWINE; VITREORETINOPATHY;

ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FEMALE; FETUS; PREGNANCY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; SWINE; THIAZOLES; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84874968703     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10418     Document Type: Article

References (62)

1. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-125.
2. Cardillo JA, Stout JT, LaBree L, et al. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology. 1997;104: 1166-1173.
3. Heimann H, Bornfeld N, FriedrichsW, et al. Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1996;234:561-568.
4. Hakin KN, Lavin MJ, Leaver PK. Primary vitrectomy for rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1993;231:344-346.
5. Saw SM, Gazzard G, Wagle AM, Lim J, Au Eong KG. An evidence-based analysis of surgical interventions for uncomplicated rhegmatogenous retinal detachment. Acta Ophthalmol Scand. 2006;84:606-612.
6. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002; 21:127-144.
7. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond). 2002;16:369-374.
8. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res. 1999;18:167-190.
9. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998;17: 77-98.
10. Bringmann A, Wiedemann P. Involvement of M̈uller glial cells in epiretinal membrane formation. Graefes Arch Clin Exp Ophthalmol. 2009;247:865-883.
11. Morino I, Hiscott P, McKechnie N, Grierson I. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Brit J Ophthalmol. 1990;74:393-399.
12. Yamashita H, Hori S, Masuda K. Population and proportion of component cells in preretinal membranes. Jpn J Ophthalmol. 1986;30:269-281.
13. Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci. 1995;36:391-405.
14. Tamiya S, Liu L, Kaplan HJ. Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Invest Ophthalmol Vis Sci. 2010; 51:2755-2763.
15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
16. Casaroli-Marano RP, Pagan R, Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40:2062-2072.
17. Sheridan CM, Magee RM, Hiscott PS, et al. The role of matricellular proteins thrombospondin-1 and osteonectin during RPE cell migration in proliferative vitreoretinopathy. Curr Eye Res. 2002;25:279-285.
18. Khankan R, Oliver N, He S, Ryan SJ, Hinton DR. Regulation of fibronectin-EDA through CTGF domain-specific interactions with TGFb2 and its receptor TGFbRII. Invest Ophthalmol Vis Sci. 2011;52:5068-5078.
19. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233:109-122.
20. Saika S, Yamanaka O, Flanders KC, et al. Epithelial-mesenchymal transition as a therapeutic target for prevention of ocular tissue fibrosis. Endocr Metab Immune Disord Drug Targets. 2008;8:69-76.
21. Imai K, Loewenstein A, Koroma B, Grebe R, de Juan E Jr. Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study. Graefes Arch Clin Exp Ophthalmol. 2000;238:440-447.
22. Fukazawa H, Li PM, Yamamoto C, Murakami Y, Mizuno S, Uehara Y. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem Pharmacol. 1991; 42:1661-1671.
23. Mahon TM, O'Neill LA. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. J Biol Chem. 1995;270:28557-28564.
24. Lei H, Rheaume MA, Velez G, Mukai S, Kazlauskas A. Expression of PDGFRa is a determinant of the PVR potential of ARPE19 cells. Invest Ophthalmol Vis Sci. 2011;52:5016-5021.
25. Andrews A, Balciunaite E, Leong FL, et al. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1999;40:2683-2689.
26. Lei H, Kazlauskas A. Growth factors outside of the plateletderived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem. 2009;284:6329-6336.
27. Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci. 2009;50:3394-3403.
28. Morales SA, Mareninov S, Prasad P, Wadehra M, Braun J, Gordon LK. Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. Exp Eye Res. 2007; 85:790-798.
29. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of plateletderived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527-1533.
30. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-6661.
31. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29:2289-2308.
32. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of cabl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22:2214-2222.
33. Choi YL, Bocanegra M, Kwon MJ, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 2010;70:2296-2306.
34. Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008;6:1766-1774.
35. Lee YC, Huang CF, Murshed M, et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene. 2010;29:3196-3207.
36. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105: 319-326.
37. Meitinger D, Hunt DM, Shih DT, Fox JC, Hunt RC. Vitreousinduced modulation of integrins in retinal pigment epithelial cells: effects of fibroblast growth factor-2. Exp Eye Res. 2001; 73:681-692.
38. Parapuram SK, Chang B, Li L, et al. Differential effects of TGFbeta and vitreous on the transformation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2009;50:5965-5974.
39. Grinnell F, Ho CH, Lin YC, Skuta G. Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices. J Biol Chem. 1999;274:918-923.
40. Sonoda S, Spee C, Barron E, Ryan SJ, Kannan R, Hinton DR. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. Nat Protoc. 2009;4: 662-673.
41. Umazume K, Barak Y, McDonald K, Liu L, Kaplan HJ, Tamiya S. Proliferative vitreoretinopathy in the swine-a new model. Invest Ophthalmol Vis Sci. 2012;53:4910-4916.
42. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991; 112:159-165.
43. Sanchez I, Martin R, Ussa F, Fernandez-Bueno I. The parameters of the porcine eyeball. Graefes Arch Clin Exp Ophthalmol. 2011;249:475-482.
44. Lalonde MR, Chauhan BC, Tremblay F. Retinal ganglion cell activity from the multifocal electroretinogram in pig: optic nerve section, anaesthesia and intravitreal tetrodotoxin. J Physiol. 2006;570:325-338.
45. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69-77.
46. Terasaki H, Miyake K, Miyake Y. Reduced oscillatory potentials of the full-field electroretinogram of eyes with aphakic or pseudophakic cystoid macular edema. Am J Ophthalmol. 2003;135:477-482.
47. Scott PA, Kaplan HJ, Sandell JH. Anatomical evidence of photoreceptor degeneration induced by iodoacetic acid in the porcine eye. Exp Eye Res. 2011;93:513-527.
48. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007;104:13283-13288.
49. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia. 2009;23: 590-594.
50. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035-1044.
51. Day E, Waters B, Spiegel K, et al. Inhibition of collageninduced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008;599: 44-53.
52. Li J, Rix U, Fang B, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010;6:291-299.
53. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473-481.
54. Blake RA, Broome MA, Liu X, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000;20:9018-9027.
55. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependent T cell activation. J Biol Chem. 1996;271:695-701.
56. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem. 2003;278:4847-4853.
57. Hakuno D, Takahashi T, Lammerding J, Lee RT. Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells. J Biol Chem. 2005;280:39534-39544.
58. Kong L, Deng Z, Shen H, Zhang Y. Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173. Mol Cell Biochem. 2011;348:11-19.
59. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
60. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
61. Guidetti B, Azema J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Curr Drug Deliv. 2008;5:7-19.
62. Bertschinger DR, Beknazar E, Simonutti M, et al. A review of in vivo animal studies in retinal prosthesis research. Graefes Arch Clin Exp Ophthalmol. 2008;246:1505-1517.